BACKGROUND: RPMI 1640 is one of the most widely used culture media for the growth of microorganisms such as Leishmania, which is typically enriched with 10-30 % of fetal bovine serum (FBS) or calf serum (FCS) due to having growth factors such as micronutrients, trace elements, and hormones.OBJECTIVES: As a result of limitations such as the high cost of commercial sera and the recent propagation of ostrich and camel breeding in our country as well as the possibility of obtaining their sera comprising growth factors similar to FBS or FCS, we decided to compare different percentages of these sera with FBS regarding the growth of two Leishmania species.METHODS: 1×106/mL of Leishmania major and Leishmania tropica were cultured in RPMI 1640 in the presence of different percentages of 2.5-30 % related to all three sera; they were then counted, compared, and analyzed on different days up to the fourteenth day.RESULTS: The highest proliferation of both Leishmania species was observed in the presence of all percentages of FBS up to day 7. In media enriched with less than 5 % of both ostrich and camel sera, the growth of the two species of Leishmania was favorable; however,with the increase in the amount of these sera, the proliferation of both species decreased. While only 10 % of sera was compared, the highest growth of L. major and L. tropica was observed in the presence of FBS followed by camel serum.CONCLUSIONS: For 5 % and less concentrations, each ostrich and camel sera and for 10 %, only camel serum are recommended as substitutes for FBS in RPMI 1640 concerning the cultivation of L. major and L. tropicafor a week of incubation;if more than 15 percent is required, FBS is still the best option.

Leishmaniasis is a zoonotic disease which is caused by protozoan parasites of the genus Leishmania. Canids are the most important reservoir of the parasites; however, limited data are available on the species of Leishmania prevalent in these animals and their impact on human health. The objective of this study was to estimate the seroprevalence of leishmaniasis in dogs from an inter-Andean region of Colombia during July 2016–July 2017, and to describe the clinical and histopathological features of the disease.

Leishmania donovani, amastigotes from dog marrow macrophages, ultrastructure

Leishmaniasis is a vector-borne zoonotic disease that is common in the world. Because of the difficulties in the treatment and control of the disease, the disease has gained popularity among researchers. Today, however, no vaccine has been developed for human protection. Considering the fact that the vector can survive in a wide ecosystem and the disease can be detected in many mammals such as humans, dogs, rodents, prevention from leishmaniasis and treatment of the disease require a combined intervention. The toxic effects of the drugs used in the treatment of leishmaniasis, the expensive treatment and the resistance of the parasite to the drug have led to the research of alternative treatment methods. This review is intended to provide an overview of leishmaniasis alternative treatment practices and to guide new researchs.

Leishmania major glycoprotein 63 (lmajgp63) gene was used in this study as DNA vaccine candidates. Gene was inserted into VR1012 plasmid by using standard molecular biology protocols, resulting in preparation of lmajgp63/VR1012 plasmid. Vaccine either used as naked or gold particles coated DNA vaccine in immunization of females Balb/c mice. Animals were immunized at week 0, 2 weeks and 6 weeks. Dermojet needle free injector had been used to deliver gold particles coated DNA vaccine intradermally (I/D) while ordinary needle injection was used to deliver naked vaccine intramuscularly (I/M). Immune response for each vaccinated group were detected, two weeks after the third administration of the vaccines, by estimation of serum concentration of IL-2, IL-4, IL-10 and INF-γ, as well as anti-soluble Leismania antigen (anti-SLA) IgG titer, by ELISA test. The results demonstrated the effectiveness of DNA vaccines in induction immune response comparing to control groups (P

Leishmania donovani, dogs (exper.), liposome-encapsulated meglumine antimoniate (LEMA) vs. unencapsulated meglumine antimoniate, LEMA was 700 times more efficacious than the encapsulated drug, liposomes can markedly reduce the drug dosage required for equivalent treatment of visceral leishmaniasis

Leishmaniasis is a zoonotic disease which has worldwide importance and is hard to control and treat. Researchers have not yet developed a protective vaccine for humans in the light of current studies. Various experimental animal models are being used since; i) Leishmania has different species and vectors, ii) there are still many clinical, pathological and immunological issues that have to be investigated, iii) new non-toxic medical recipes to have maximum yield in a short time have to be investigated, iv) protective vaccination have to be developed. Mouse, hamster, dog, rodent, and non-human primates are among these animal models. None of them has the same clinical features, pathogenesis and immunology with the disease in human. However, rodents, dogs, and monkeys, which are the last host of the parasite, are among the most preferred models in recent days. Considering the different clinical forms of the disease, it is best to decide which Leishmania species to work with which animal. This review is intended to guide the researchers in choosing an appropriate animal model for leishmaniasis studies.

The efficacy of the in vitro cultivation of promastigotes of threeLeishmania spp. weretested inmodified the biphasic Novy-MacNealNicolle (NNN) medium prepared using blood from different mammals ( human bloodgroup O , horse, donkey, goat and sheep).This study was carried out to determine which modification of NNN media will begave the best yield in the shortest time fordifferent parasite species, in order to obtaina large crop of promastigotes for experimental work and for antigen preparation.Promastigotes of the three main parasite species ,Leishmaniadonovani,Leishmaniatropica and Leishmania major, isolated from patient in Bagdad andcultuerd, at equal numbers, in the 5 different NNN preparations. At the end of the 7thday, the NNN medium using horse blood produced the greatest number ofpromastigotes for all Leishmania spp. tested, 27 ,15 ,33x106 whilst goat blood providthe poorest medium, providing culture results only for L. donovani,7x106.Humanblood group O give good results, 9.2 ,5,4X106.Donkey blood 6.5,2 ,1 X106.ThenSheep blood gave 4.5, 2.5 X106 ,This finding may be explained by the fact thatLeishmaniais a nicotinamide adenine dinucleotide (NAD) auxotrophand horseerythrocytes support NAD-dependent microorganisms

<p>A Leishmaniose visceral em cães é descrita como uma doença de caráter crônico na qual os principais sintomas são perda progressiva de peso, caquexia e lesões dermatológicas. Recentemente, a doença tem sido relacionada com alterações neurológicas. Um total de 40 cães portadores de leishmaniose visceral foi dividido em dois grupos. O primeiro composto por cães sem sintomas neurológicos (n=30) e o segundo grupo composto por cães com sintomas neurológicos (n=10). Amostras de encéfalo foram coletadas e armazenadas em formalina tamponada, para realização de imunoistoquímica para a pesquisa de formas amastigotas de <em>Leishmania (Leishmania) infantum chagasi</em>, linfócitos T CD3+, CD4+ e CD8+ e macrófagos. A reação de imunoistoquímica não revelou formas amastigotas do parasita. Linfócitos T estavam presentes em 24/30 (80%) dos cães sem sintomas neurológicos e em todos os cães do segundo grupo (p=0,0011). Linfócitos CD4+ e CD8+ raramente foram observados, apresentando imunomarcação para CD4+ em 10/40 (25%) dos cães e em metade dos animais do grupo neurológico (p=0,0090). A presença de CD8+ foi detectada em 4/10 (40%) cães com doenças neurológicas (p=0,0021). Macrófagos foram observados em 38/40 (95%) cães, sem diferença estatística significante entre os dois grupos (p= 0,7664).</p> | <p>Visceral leishmaniasis in dogs is described as a chronic disease whose main symptoms are progressive weigth loss, cachexy and dermatologic lesions. Recently, the disease has been associated to neurologic disorders. A total of 40 dogs with visceral leishmaniasis were divided into two groups. The first composed of dogs without neurological signs (n=30) and the second by dogs with neurological disorders (n=10). Brain samples were collected, stored in 10% buffered formalin and subjected to immunohistochemical examination for amastigotes forms of <em>Leishmania (Leishmania) infantum chagasi, </em>CD3+, CD4+ and CD8+ T lymphocytes and macrophages. Imunnohistochemistry evaluation revealed no amastigote forms of the parasite. CD3+ T lymphocytes were present in 24/30 (80%) dogs without neurological signs and in all dogs from the second group (p=0.0011). CD4+ and CD8+ were rarely observed, with CD4+ immunostaining in 10/40 (25%) dogs, from which half of them had neurological disease (p=0.0090). The presence of CD8+ was detected only in 4/10 (40%) dogs from neurological group (p=0.0021). Macrophages were detected in 38/40 (95%) dogs, without significant differences between groups (p=0.7664).</p>

A Leishmaniose visceral em cães é descrita como uma doença de caráter crônico na qual os principais sintomas são perda progressiva de peso, caquexia e lesões dermatológicas. Recentemente, a doença tem sido relacionada com alterações neurológicas. Um total de 40 cães portadores de leishmaniose visceral foi dividido em dois grupos. O primeiro composto por cães sem sintomas neurológicos (n=30) e o segundo grupo composto por cães com sintomas neurológicos (n=10). Amostras de encéfalo foram coletadas e armazenadas em formalina tamponada, para realização de imunoistoquímica para a pesquisa de formas amastigotas de Leishmania (Leishmania) infantum chagasi, linfócitos T CD3+, CD4+ e CD8+ e macrófagos. A reação de imunoistoquímica não revelou formas amastigotas do parasita. Linfócitos T estavam presentes em 24/30 (80%) dos cães sem sintomas neurológicos e em todos os cães do segundo grupo (p=0,0011). Linfócitos CD4+ e CD8+ raramente foram observados, apresentando imunomarcação para CD4+ em 10/40 (25%) dos cães e em metade dos animais do grupo neurológico (p=0,0090). A presença de CD8+ foi detectada em 4/10 (40%) cães com doenças neurológicas (p=0,0021). Macrófagos foram observados em 38/40 (95%) cães, sem diferença estatística significante entre os dois grupos (p= 0,7664).